Having trouble reading this email? View online.


Archive Volume 16, Issue 1 January/February 2015
Published by the Hemophilia Association of the Capital Area | HACAcares.org


New drugs offer hope, barriers for hepatitis C patients
The Inquirer

For patients with hepatitis C, the last year has brought great hope: New drugs that are highly effective with few side effects. But their high cost has led Medicaid officials in Pennsylvania and other states to put up barriers for patients, treating only the sickest ones and leaving many others to wait.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Inhibitor development risk in patients with hemophilia higher than previously thought
HCPLive

Inhibitor development in patients with mild hemophilia A is a larger risk than previously anticipated, though desmopressin may help, according to a literature review published in the journal Blood. Researchers from the Hemophilia and Thrombosis Center at the San Bortolo Hospital in Vicenza, Italy, reviewed the current literature surrounding mild hemophilia A patients, which they defined as factor VIII or factor IX (FVIII and FIX, respectively) between 5 and 40 U/dL.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


US guidelines on prevention with people living with HIV now emphasise engagement with care, HIV treatment and social factors
Aidsmap

The American public health agency, the Centers for Disease Control and Prevention prevention interventions and advice that should be offered to people who are HIV positive. The CDC last issued guidelines on what is sometimes called 'prevention with positives' in 2003. Those guidelines ran to 24 pages and emphasised screening for behavioural risk factors and sexually transmitted infections, one-to-one prevention counselling and advice delivered by clinicians, other behavioral interventions and partner notification.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Long-term relief for hemophilia B patients
HCPLive

Gene therapy provided safe and long-term relief for patients with severe hemophilia B, according to findings reported in The New England Journal of Medicine. Researchers from St. Jude Children's Research Hospital evaluated the stability of transgene expression and long-term safety in 10 male patients with severe hemophilia B
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Hepatitis C market competition arrives for 2015
Forumulary Journal

There is plenty of activity already in the hepatitis C market as competition has arrived for 2015, including CVS Health versus Express Scripts and Gilead Sciences versus AbbVie, over FDA-approved hepatitis C treatments. This will have implications for retail prescriptions as well as continuity-of-care programs within non-Medicare accountable care organizations and health systems.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


The challenge of creating an HIV vaccine: Virus infects very cells induced by drug
Medical Daily

The reason there's no vaccine for HIV/AIDS, the National Institutes of Health explains, is because HIV has "unique ways of evading the immune system, and the human body seems incapable of mounting an effective immune response against it." A recently published animal study further clarifies the problem by showing how vaccines designed to protect against HIV backfire, leading to an increase, not decrease, in new infections.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Broad immune response may be needed to destroy latent HIV
YaleNews

A major barrier to finding a cure for HIV/AIDS is the presence of latent HIV in the cells of chronically infected individuals. But a team of Yale and Johns Hopkins researchers may have pinpointed a strategy for eliminating the residual virus.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Hepatitis C treatments are 'history in the making' at a high cost
Ottawa Citizen

BillyBob McPherson lived on Ottawa's streets as a young teenager before "running away with the carnival." The 55-year-old doesn't know exactly when during his colorful life he contracted hepatitis C — he thinks it might have been in Texas in the 1980s where he had surgery and blood transfusions while working as a carny.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments
in-PharmaTechnologist

Gilead and AbbVie's exclusive deals with payers CVS and Express Scripts could help cut the cost of the new class of treatments for America’s three million Hepatitis C sufferers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Hemophilia cured in mice models using new genome editing method
HCPLive

Stanford researchers were able to cure hemophilia in mice models using a new genome editing method. Their findings were published in Nature. A safer genome editing method might cure hemophilia in mice, according to research published in the journal Nature.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




This email was sent by the Hemophilia Association of the Capital Area, powered by Powered by Corporate Briefs
Engage your customer base. Launch your Corporate Brief today.

Archive | View Online